Pfizer beats out Novo with $10B agreement to buy Metsera
After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has prevailed in its pursuit of obesity biotech…
ESMO: Pfizer sees year-long weight gain in cancer patients with wasting condition
For the second year running, Pfizer has arrived at the European Society for Medical Oncology (ESMO) conference armed with data showing its one-time heart failure hopeful ponsegromab can treat a…